Clinical Trial Detail

NCT ID NCT01219699
Title A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

estrogen-receptor positive breast cancer

Advanced Solid Tumor

Therapies

Alpelisib

Alpelisib + Fulvestrant

Age Groups: senior adult

Additional content available in CKB BOOST